2019 Related Topics 
Pharmaceutical Technology
MARCH 18, 2024
Using GlobalData’s POLI & HTA database, analysis has been conducted that will provide insight into how the HTA landscape adapted between 2019 and 2023.
MedCity News
JANUARY 17, 2023
in 2019, according to a recent report from HHS. The uninsured rate declined to 10.5% in 2021 from 11.1% Some of the largest gains in coverage were among demographic groups that historically have had higher uninsured rates, such as younger adults, Latino individuals, American Indian/Alaska Natives and non-English speaking adults.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JULY 17, 2023
billion for phased clinical trials of US Food and Drug Administration (FDA)-approved drugs between 2010-2019. million publications describing basic or applied research related to 386 of 387 drugs approved 2010-2019 with $8.1 This was ~10 percent of reported industry spending. billion (3.3
Fierce Pharma
APRIL 23, 2024
Dating to a 2019 clinical hold of a phase 3 trial, getting its gene therapy ra | Dating to a 2019 clinical hold, getting its gene therapy pz-cel across the FDA finish line has been a challenge for troubled Abeona Therapeutics. Now the wait continues as the FDA has rejected the treatment due to CMC issues.
Advertiser: ZoomInfo
In 2019, DiscoverOrg commissioned Forrester Consulting to evaluate sales and marketing intelligence practices in the B2B space. Fact: Only 8% of sales and marketing professionals say their data is between 91% - 100% accurate. The primary takeaway? Forrester found “only 1.2%
Fierce Pharma
MARCH 5, 2024
Vanda has been waiting years for an FDA hearing to contest the agency’s 2019 rejection of its sleep drug Hetlioz in jet lag disorder. Vanda has been waiting years for an FDA hearing to contest the agency’s 2019 rejection of its sleep drug Hetlioz in jet lag disorder. regulator, the FDA has crushed Vanda’s bid.
Fierce Pharma
MARCH 19, 2024
After a year marked by Gilead's oncology push and an ongoing focus on CAR-T therapies, CEO Daniel O’Day collected his largest total compensation package since the year he arrived at the Califo | The CEO collected his highest total compensation package since his first year in the role in 2019.
Advertiser: ZoomInfo
In this report, ZoomInfo substantiates the assertion that technographic data is a vital resource for sales teams. In fact, the majority of respondents agree—with 72.3% reporting that technographic data is either somewhat important or very important to their organization.
Expert insights. Personalized for you.
52 
Let's personalize your content